Skip to content
Close
SEARCH
CONTACT US
CONTACT US

OUR SERVICES

We take a personalized and integrated approach to help our clients position their pipelines and companies for success offering a full range of development and commercialization services.

VIEW ALL SERVICES
PHASES
DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
CLINICAL DEVELOPMENT
Advance through clinical
development and health
authority review with confidence.
ALL STAGES
Benefit from our expertise
across all phases
of drug development.
PRECLINICAL
Navigate the critical
preclinical testing phase
with expert guidance.
COMMERCIALIZATION
Successfully bring your
product to market with
our commercialization support.
ALL SERVICES
Access comprehensive
services for every stage
of product development.

ABOUT US

We are Halloran, a life science consulting firm, partnering to enrich your product development and business growth. We propel your organization further; positively impacting the health and wellbeing of patients around the world.

LEARN MORE ABOUT US
EXPERTISE WITH PERSONALITY
OUR FOUNDER
Discover the visionary
leader driving Halloran's
success and innovation.
STRATEGIC PARTNERS
Meet our trusted
strategic partners who
enhance our capabilities.
WHY HALLORAN?
Explore the unique reasons
why clients choose
Halloran for their needs.
OUR TEAM
Get to know the dedicated
professionals who make
up the Halloran team.
CAREERS
Join our dynamic team
and advance your
career with Halloran.
LEARN MORE
Find out more about
Halloran's comprehensive
services and expertise.
hcg-service-hero-1

Insights From Halloran

Josh WootenMay 8, 2025 7:57:17 AM1 min read

Start it off Right: The Importance of Building an IND from High-Quality Nonclinical Reports

Nonclinical reports are one of the most critical pieces for building an IND, but are ...
Start Reading
Meghan Patterson, MPHMay 2, 2025 11:23:42 AM3 min read

Balancing Simplicity and Complexity in Clinical Trial Design

Designing clinical trials is a nuanced process that often pits the ideal of simplicity ...
Start Reading
Steve Kornher, PhDApr 28, 2025 3:12:28 PM8 min read

Risk Mitigation Planning for Pharmaceutical Tariffs

The impact of tariffs on the pharmaceutical and biotechnology industries is unclear as ...
Start Reading
Meghan Patterson, MPHApr 22, 2025 12:32:06 PM4 min read

ICH E6(R3) and a Risk-Based Approach as a Competitive Advantage 

By Meghan Patterson
Start Reading
Elizabeth BodiApr 14, 2025 5:52:43 PM1 min read

Key Update on Guideline for Good Clinical Practice E6(R3)

January 6, 2025: ICH assembly agreed that ICH GCP E6 R3 Principles and Annex 1 could be ...
Start Reading
Mike Fusakio PhDApr 14, 2025 4:38:00 PM2 min read

Impact on Product Development: FDA Phasing Out Animal Testing Requirement

Contributing Author: Hema Balasubramanian The FDA announcement on its plan to phase out ...
Start Reading
Carolina Ahrendt, MBA, PMPApr 10, 2025 12:40:26 PM6 min read

Ticking Timeline: Tips for Effective Product Development Timelines

Once a biotech or pharmaceutical company defines their product development objectives ...
Start Reading
Sheila GwizdakApr 7, 2025 9:34:32 AM1 min read

Impacts of ICH GCP E6 (R3) Webinar

Join Halloran Consulting Group for a compelling discussion on how to future-proof your ...
Start Reading
Kanchana IyerApr 3, 2025 10:30:00 AM3 min read

Navigating Drug, Biologic and Medical Device Regulatory Strategies

Contributing Author: Mamta Puri-Lechner In a recent webinar, Kanchana Iyer and Mamta ...
Start Reading
Daniel SmithMar 12, 2025 10:21:13 AM1 min read

FDA Announces Key Transition Dates for ESG NexGen

Halloran participated in the User Acceptance Testing last summer/fall and is excited ...
Start Reading
Load more posts